Endothelial cells influence the sodium nitroprusside mediated inhibition of platelet aggregation by an as yet unkown pathway

Thrombosis Journal

Jens M Klinge¹  Jörg Dötsch¹  Wolfgang Rascher¹  Manfred Rauh¹  Hans-Georg Topf¹ 

[1]Klinik für Kinder und Jugendliche, University of Erlangen-Nuremberg, Loschgestr 15, 91054, Erlangen, Germany

关键词: Endothelial cells;    Cyanide;    Sodium-nitro-prusside (SNP);    Platelet aggregation;    Nitric oxide (NO);   

Others  :  838958
DOI  :  10.1186/1477-9560-10-6

 received in 2011-05-25, accepted in 2012-03-13,  发布年份 2012

【 摘 要 】

The clinical use of Sodium nitroprusside (SNP) may be associated with an alteration of platelet function. The main focus of this study was the effect of SNP on platelet aggregation in the absence or presence of endothelial cells.

Methods: Platelets were incubated with different concentrations of SNP with and without endothelial cells. Platelet aggregation was induced by ADP.

Results: Platelet aggregation was significantly inhibited by all concentrations of SNP. Endothelial cells significantly increased this inhibitory effect of SNP. Time course studies showed an inverse correlation of incubation time to platelet aggregation inhibition in the absence of endothelial cells, and a direct correlation in the presence of endothelial cells. Blocking platelet and endothelial cell guanylate cyclase with 1 H-(1,2,4)-oxadiazolo(4,3-a) quinoxalin-1-one (ODQ), or pretreatment of the endothelial cells with cyclooxygenase – inhibitors, had no influence on the increased inhibitory effect of the endothelial cells. Cyanide reversed the inhibitory effect of SNP completely.

Conclusion: Endothelial cells play an important role in the SNP mediated inhibition of platelet aggregation. The effect is reversible only by cyanide, not by blocking classical NO signal transduction.

【 授权许可】

   
2012 Topf et al.; licensee BioMed Central Ltd

【 参考文献 】

• [1]Benitz WE, et al.: Use of sodium nitroprusside in neonates: efficacy and safety. J Pediatr 1985, 106(1):102-110.
• [2]Patel HP, Mitsnefes M: Advances in the pathogenesis and management of hypertensive crisis. Curr Opin Pediatr 2005, 17(2):210-214.
• [3]Palhares DB, Figueiredo CS, Moura AJ: Endotracheal inhalatory sodium nitroprusside in severely hypoxic newborns. J Perinat Med 1998, 26(3):219-224.
• [4]Schreiber MD, et al.: Direct comparison of the effects of nebulized nitroprusside versus inhaled nitric oxide on pulmonary and systemic hemodynamics during hypoxia-induced pulmonary hypertension in piglets. Crit Care Med 2002, 30(11):2560-2565.
• [5]Brune B, Hanstein K: Rapid reversibility of nitric oxide induced platelet inhibition. Thromb Res 1998, 90(2):83-91.
• [6]Mellgren K, et al.: Effect of nitric oxide gas on platelets during open heart operations. Ann Thorac Surg 1998, 65(5):1335-1341.
• [7]Moro MA, et al.: cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A 1996, 93(4):1480-1485.
• [8]Jensen BO, et al.: Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin- induced platelet shape change. Platelets 2011, 22(1):7-18.
• [9]Negrescu EV, et al.: Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside. Cardiovasc Drugs Ther 1995, 9(4):619-629.
• [10]Suzuki Y, et al.: Synergistic disaggregation of platelets by the products of endothelial cells or their analogs. Haematologia (Budap) 2000, 30(2):81-90.
• [11]Radomski MW, et al.: Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res 1993, 27(7):1380-1382.
• [12]Kurata M, Tanaka K, Usami M: Different roles of endothelium-derived substances on inhibiting platelet aggregation in whole blood. Gen Pharmacol 1997, 28(5):671-673.
• [13]Cheung PY, et al.: Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates. Lancet 1998, 351(9110):1181-1182.
• [14]Radomski MW, Palmer RM, Moncada S: The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987, 92(3):639-646.
• [15]Radomski MW, Palmer RM, Moncada S: Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987, 92(1):181-187.
• [16]Nielsen VG, Geary BT, Baird MS: Effects of DETANONOate, a nitric oxide donor, on hemostasis in rabbits: an in vitro and in vivo thrombelastographic analysis. J Crit Care 2000, 15(1):30-35.
• [17]Dambisya YM, Lee TL: A thromboelastography study on the in vitro effects of L-arginine and L- NG-nitro arginine methyl ester on human whole blood coagulation and fibrinolysis. Blood Coagul Fibrinolysis 1996, 7(7):678-683.
• [18]Williams RH, Nollert MU: Platelet-derived NO slows thrombus growth on a collagen type III surface. Thromb J 2004, 2(1):11. BioMed Central Full Text
• [19]Gold ME: Pharmacology of the nitrovasodilators. Antianginal, antihypertensive, and antiplatelet actions. Nurs Clin North Am 1991, 26(2):437-450.
• [20]Erne P, et al.: Vasodilating agents and platelet function: intracellular free calcium concentration, cyclic nucleotides, and shape-change response. J Cardiovasc Pharmacol 1986, 8(Suppl 8):S102-S106.
• [21]Woods JD, Edwards JS, Ritter JM: Inhibition by nitroprusside of platelet calcium mobilization: evidence for reduced sensitivity to nitric oxide in essential hypertension. J Hypertens 1993, 11(12):1369-1373.
• [22]Sogo N, et al.: Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun 2000, 279(2):412-419.
• [23]Salvemini D, et al.: Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A 1993, 90(15):7240-7244.
• [24]Salvemini D, Masferrer JL: Interactions of nitric oxide with cyclooxygenase: in vitro, ex vivo, and in vivo studies. Methods Enzymol 1996, 269:12-25.
• [25]Vane JR, Anggard EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 1990, 323(1):27-36.
• [26]Levin RI, Weksler BB, Jaffe EA: The interaction of sodium nitroprusside with human endothelial cells and platelets: nitroprusside and prostacyclin synergistically inhibit platelet function. Circulation 1982, 66(6):1299-1307.
• [27]Dotsch J, et al.: Recovery from withdrawal of inhaled nitric oxide and kinetics of nitric oxide-induced inhibition of nitric oxide synthase activity in vitro. Intensive Care Med 2000, 26(3):330-335.
• [28]Klinge JM, et al.: Endothelial cells play an important role in the antiaggregatory effect of nitric oxide. Crit Care Med 2003, 31(7):2010-2014.
• [29]Konturek SJ, Pawlik W: Physiology and pharmacology of prostaglandins. Dig Dis Sci 1986, 31(2 Suppl):6S-19S.
• [30]Brune B, Zhou J, von Knethen A: Nitric oxide, oxidative stress, and apoptosis. Kidney Int Suppl 2003, 84:S22-S24.